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Anemia Protein, FANCD2, Sustain a Signiﬁcant Group of FA-D2
Patients with Severe Phenotype
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FANCD2 is an evolutionarily conserved Fanconi anemia (FA) gene that plays a key role in DNA double-strand–type
damage responses. Using complementation assays and immunoblotting, a consortium of American and European groups
assigned 29 patients with FA from 23 families and 4 additional unrelated patients to complementation group FA-D2.
This amounts to 3%–6% of FA-affected patients registered in various data sets. Malformations are frequent in FA-D2
patients, and hematological manifestations appear earlier and progress more rapidly when compared with all other
patients combined (FA–non-D2) in the International Fanconi Anemia Registry. FANCD2 is ﬂanked by two pseudogenes.
Mutation analysis revealed the expected total of 66 mutated alleles, 34 of which result in aberrant splicing patterns.
Many mutations are recurrent and have ethnic associations and shared allelic haplotypes. There were no biallelic null
mutations; residual FANCD2 protein of both isotypes was observed in all available patient cell lines. These analyses
suggest that, unlike the knockout mouse model, total absence of FANCD2 does not exist in FA-D2 patients, because of
constraints on viable combinations of FANCD2 mutations. Although hypomorphic mutations arie involved, clinically,
these patients have a relatively severe form of FA.
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Fanconi anemia (FA) is a rare genome-instability disorder
with the variable presence of congenital malformations,
progressive bone-marrow failure (BMF), predisposition to
malignancies, and cellular hypersensitivity to DNA-inter-
strand crosslinking agents.1 There are at least 13 comple-
mentation groups (FA-A [MIM 607139], -B [MIM 300515],
-C [MIM 227645], -D1 [MIM 600185], -D2 [MIM 227646],
-E [MIM 600901], -F [MIM 603467], -G [MIM 602956], -I
[MIM 609053], -J [MIM 609054], -L [MIM 608111], -M
[MIM 609644], and -N [MIM 610355]), each of which is
associated with biallelic or hemizygous mutations in a dis-
tinct gene.2–4 To date, 12 of the underlying genes have
been identiﬁed: FANCA, FANCB, FANCC, FANCD1/BRCA2,
FANCD2, FANCE, FANCF, FANCG/XRCC9, FANCJ/BRIP1,
FANCL/PHF9, FANCM/HEF, and FANCN/PALB2.3–7 Eight of
the FA proteins (FANCA, -B, -C, -E, -F, -G, -L, and -M) and
other components assemble in a nuclear complex, the FA
“core complex,” that is required for the monoubiquitin-
ation of FANCD2 at amino acid residue K561.8,9 Mono-
ubiquitination occurs in response to DNA damage and dur-
ing the S phase of the cell cycle.9,10 Themonoubiquitinated
FANCD2 isoform (FANCD2-L, as opposed to FANCD2-S)
is targeted to nuclear foci containing proteins such as
BRCA1 [MIM 113705], BRCA2, and RAD51 [MIM 179617]
that are involved in DNA-damage signaling and recom-
binational repair.11–14 The precise role of FANCD2 remains
unknown, but FANCD2-deﬁcient DT40 cells show defects
in homologous recombination-mediated DNA double-
strand break (DSB) repair, translesion synthesis, and gene
conversion.11,15,16 Therefore, FANCD2 is thought to play a
central role in the maintenance of genome stability.11,16,17
The human and murine Fancd2 genes show a higher
degree of homology than do the corresponding Fanca,
Fancc, Fance, Fancf, and Fancg genes.18 Fancd2-knockout
mice suffer from perinatal lethality, microphthalmia, and
early epithelial cancers,19 but it remains controversial
whether the murine FA-D2 phenotype in general is more
severe than the corresponding murine knockouts of the
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Figure 1. Circular map of vector S11FD2IN. The retroviral-ex-
pression vector S11FD2IN contains a bicistronic construct of the
full-length FANCD2 cDNA (“FANCD2”) and the neomycin resistance
gene (NEO). Translation of the latter is ensured by an IRES. Also
shown are the long terminal repeats (LTR), the restriction sites
and their positions, and the bacterial resistance (AmpR). Used for
cloning of FANCD2 into the target vector S11IN were the 5′ EcoRI
and the 3′ SalI (insert) and BamHI (vector) sites; the latter two
were destroyed by blunting.
Table 1. FANCD2 cDNA Ampliﬁcation Primers
PCR
Fragment
Forward Reverse
PCR
Product
Size
(bp)Designation
Binding
Position
Sequence
(5′r3′) Designation
Binding
Position
Sequence
(5′r3′)
1 FA-D2, Fr.1 F 47 to 27 GCGACGGCTTCTCGGAAGTAA FA-D2, Fr.1 R 998 to 976 CTGTAACCGTGATGGCAAAACAC 998
2 FA-D2, Fr.2 F 763 to 787 GACCCAAACTTCCTATTGAAGGTTC FA-D2, Fr.2 R 1996 to 1975 CTACGAAGGCATCCTGGAAATC 1,234
3 FA-D2, Fr.3 F 1757 to 1777 CGGCAGACAGAAGTGAATCAC FA-D2, Fr.3 R 2979 to 2958 GTTCTTGAGAAAGGGGACTCTC 1,223
4 FA-D2, Fr.4 F 2804 to 2829 TTCTACATTGTGGACTTGTGACGAAG FA-D2, Fr.4 R 3942 to 3922 GTCTAGGAGCGGCATACATTG 1,139
5 FA-D2, Fr.5(L) F 3761 to 3781 CAGCAGACTCGCAGCAGATTC FA-D2, Fr.5(L) R 4700 to 4679 GACTCTGTGCTTTGGCTTTCAC 940
other FA genes.19,20 Fancd2 is required for survival after
DNA damage in Caenorhabditis elegans.21 Fancd2-deﬁcient
zebraﬁsh embryos display severe developmental defects
due to increased apoptosis, which underscores the im-
portance of Fancd2 function during vertebrate ontogen-
esis.22 Finally, knock-down ofDrosophila Fancd2 causes pu-
pal lethality.23 In humans, it has been estimated that com-
plementation group FA-D2 accounts for between !1%24 and
3%25 of all patients with FA. The presence of FANCD2pseu-
dogenes complicates mutation analysis, which may ex-
plain why there has been just one other report of a single
human FANCD2 mutation since the original descrip-
tion.26,27 As a concerted effort among nine laboratories, we
present a comprehensive mutation proﬁle of the FANCD2
gene (Ensembl Genome Browser [accession number
ENSG00000144554]). We show that the FA phenotype re-
sulting from FANCD2 deﬁciency is relatively severe. In
contrast to all other FA genes, (1) the mutation spectrum
of FANCD2 is dominated by splicing mutations, and (2)
residual FANCD2 protein exists in all tested cell lines from
FA-D2 patients, which suggests lethality of biallelic null
mutations.
Patients, Material, and Methods
Diagnostic Procedures
Anticoagulated peripheral blood and skin-biopsy samples were
referred to the participating laboratories for diagnostic testing.
Conﬁrmation of the diagnosis of FA, subtyping, and mutation
analysis were performed with informed consent according to the
Declaration of Helsinki. The study was approved by the institu-
tional review boards of the participating centers. Clinical suspi-
cion of FA was conﬁrmed by the detection of cellular hypersen-
sitivity to DNA-crosslinking agents following published proce-
dures.28–32 In patients with increasing and/or long-term stable
blood counts, the possibility of somatic reversion leading to mo-
saicism of hematopoietic cells was considered, and cultured ﬁ-
broblasts were used for mitomycin-C (MMC) sensitivity testing
and for complementation studies.
Patient Statistics
A total of 29 fully informative FA-D2 patients (patients 1–29)were
included in the present genotype-phenotype study. A fetal case
(number 19) and ﬁve patients with hematopoieticmosaicism (pa-
tients 3, 14, 15, 25, and 26) were excluded from clinical follow-
up studies. Four additional FA-D2 patients (patients 30–33) with
incomplete clinical data were not part of the phenotype analysis,
but results concerning their mutations are indicated in the text,
tables, and ﬁgures.
Three end points were evaluated to determine hematologic se-
verity: time to hematological onset, deﬁned as “cell count of at
least one lineage constantly below normal range”; period from
BMF to hematological stem-cell transplantation (HSCT); and time
to HSCT. Kaplan-Meier estimates were computed for the length
of overall survival. Birth was taken as the date of FA onset for all
these calculations. Comparisons were made with patients in the
International Fanconi Anemia Registry (IFAR), as reported else-
where,33 by means of log-rank test statistics. Multivariate and
competing-risk analyses were not possible because of the limited
number of informative patients.
Cell Culture
Epstein-Barr virus (EBV)–transformed lymphoblastoid cell lines
(LCLs) were established using cyclosporin A, as described else-
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Table 2. FANCD2 cDNA Sequencing Primers
Designation
Binding
Position
Sequence
(5′r3′)
sFA-D2, 244 F 244 to 263 ACCCTGAGGAGACACCCTTC
sFA-D2, 545 F 545 to 566 GGCTTGACAGAGTTGTGGATGG
sFA-D2, 1011 F 1011 to 1033 CAGCGGTCAGAGCTGTATTATTC
sFA-D2, 1308 F 1308 to 1327 GTCGCTGGCTCAGAGTTTGC
sFA-D2, 1574 F 1574 to 1596 CCCCTCAGCAAATACGAAAACTC
sFA-D2, 2142 F 2142 to 2162 GGTGACCTCACAGGAATCAGG
sFA-D2, 2381 F 2381 to 2404 GAGAGATTGTAAATGCCTTCTGCC
sFA-D2, 2679 F 2679 to 2699 TGACCCTACGCCATCTCATAG
sFA-D2, 3268 F 3268 to 3288 GCCCTCCATGTCCTTAGTAGC
sFA-D2, 3573 F 3573 to 3594 GCACACAGAGAGCATTCTGAAG
sFA-D2, 4049 F 4049 to 4069 ACACGAGACTCACCCAACATG
sFA-D2, 4303 F 4303 to 4323 GAGTCTGGCACTGATGGTTGC
sFA-D2, 367 R 367 to 347 CATCCTGCAGACGCTCACAAG
sFA-D2, 621 R 621 to 600 CAGGTTCTCTGGAGCAATACTG
sFA-D2, 951 R 951 to 929 CTGTAACCGTGATGGCAAAACAC
sFA-D2, 1158 R 1183 to 1158 TCTGAGTATTGGTGCTATAGATGATG
sFA-D2, 1414 R 1414 to 1396 CCTGCTGGCAGTACGTGTC
sFA-D2, 1704 R 1704 to 1684 GAATACGGTGCTAGAGAGCTG
sFA-D2, 2253 R 2253 to 2232 CTCCTCCAAGTTTCCGTTATGC
sFA-D2, 2526 R 2526 to 2505 GTTTCCAAGAGGAGGGACATAG
sFA-D2, 3346 R 3346 to 3328 GGACGCTCTGGCTGAGTAG
sFA-D2, 3674 R 3674 to 3653 GTAGGGAATGTGGAGGAAGATG
sFA-D2, 4159 R 4159 to 4139 CCAGCCAGAAAGCCTCTCTAC
sFA-D2, 4409 R 4409 to 4387 GGGAATGGAAATGGGCATAGAAG
Table 3. FANCD2 Superamplicon Primers
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
where.34 All blood-derived cell cultures were maintained in RPMI
1640 medium with GlutaMAX (Gibco) supplemented with 15%
fetal bovine serum (FBS) (Sigma). Fibroblast strains were estab-
lished using standard cell-culture procedures and were propa-
gated in Earle’s minimal essential medium with GlutaMAX
(Gibco) and 15% FBS. All cultures were kept in high-humidity
incubators in an atmosphere of 5% (v/v) CO2 and, in the case of
ﬁbroblasts, 5% (v/v) O2 by replacing ambient air with nitrogen.
35
MMC treatment was for 48 h at 12 ng/ml (ﬁbroblasts) or 15 ng/
ml (LCLs) to cause cell-cycle arrest, or for 12 h at 100 ng/ml to
induce monoubiquitination of the protein, FANCD2-L. In some
cases, RNA stabilization was achieved by the addition of cyclo-
heximide (CHX) to cell cultures at a ﬁnal concentration of 250
mg/ml 4.5 h before RNA isolation.
Retroviral Complementation
For construction of the D2-IRES (internal ribosomal entry site)–
neo retroviral expression vector S11FD2IN, the D2-IRES-puro
plasmid pMMP-FANCD226 was cut using SalI. The ends were
blunted, and the fragment containing the FANCD2 ORF was cut
out with EcoRI and was ligated into S11IN, which was cut with
BamHI, was blunted, and was cut again with EcoRI (ﬁg. 1). S11
vectors are based on the spleen focus–forming virus and are de-
rived from the GR plasmid.36 Sequencing of the retroviral plasmid
S11FD2IN revealed three reported polymorphisms in the FANCD2
ORF—c.1122ArG, c.1509CrT, and c.2141CrT26—and another si-
lent base substitution, c.3978CrT. Stable retroviral packaging
cells were generated by infection of PG13 cells and selection in
G418 (Sigma), as described elsewhere.37 In addition, the cDNAs
encoding enhanced green ﬂuorescent protein (GFP) and FANCA
cDNAs were separately cloned into the vector S11IN for trans-
duction of the cells under study, with GFP serving to monitor
complete selection and FANCA serving as negative complemen-
tation control.
Retroviral transduction of cultured cells followed published
protocols.38,39 Selection of transduced cells was in G418 (Sigma)
at a ﬁnal concentration of 0.8–1.2 mg/ml for ∼10 d. Transduced
cells were analyzed for their sensitivity to MMC, with use of ﬂow
cytometry, to assess survival rates and cell-cycle arrest.39,40
Immunoblotting
FANCD2 immunoblottingwas performed as described elsewhere,9
with minor modiﬁcations. Detection was by the chemilumines-
cence technique with use of standard enhanced chemolumines-
cence reagent (Amersham) or SuperSignalWestFemto (Pierce).
Mutation and Haplotype Characterization
Primers used for cDNA ampliﬁcation are shown in table 1, and
those additionally used for cDNA sequencing are shown in table
2 (GenBank accession numbers NM_033084 and AF340183).
A total of seven large amplicons (superamplicons) were gen-
erated with primers that are unique to certain regions of the
functional FANCD2 gene. These primers and the sizes of the su-
peramplicons I–VII are shown in table 3. The superamplicons
served as templates in place of genomic DNA. They were used to
amplify the genomic sequence before sequencing; an exception
to this was superamplicon V, which was used for direct sequenc-
ing. Genomic primers for the ampliﬁcation of all FANCD2 exons
and adjacent intron regions and their sizes are displayed in table
4. Additional genomic mutation-speciﬁc primers are shown in
table 5.
For haplotyping, four microsatellite markers ﬂanking FANCD2
on chromosome 3 were studied: D3S1597, a dinucleotide re-
peat at 9.340 Mb; D3S1038, a dinucleotide repeat at 10.488
Mb; D3S3611, another dinucleotide repeat at 10.529 Mb; and
D3S1675, a tetranucleotide repeat at 10.643 Mb. Primers used for
microsatellite ampliﬁcations are speciﬁed in table 6. Two of the
forward primers were 5′-Cy5-; the other two 5′-Cy5.5- primers
were labeled for multiplex fragment analysis with DNA Sizing
standards on a CEQ 8000Genetic Analysis System (bothBeckman
Coulter).
Results
Assignment to and Frequency of Group FA-D2
Figure 2 demonstrates our strategy for the assignment of
cultured FA cells to group FA-D2. MMC sensitivity was
demonstrated by cell-cycle analysis that showedG2-phase
arrest of the tested LCLs (ﬁg. 2B, lane 2).30–32 The apparent
absence of FANCD2 bands on standard-exposure immu-
noblots suggested their belonging to complementation
group FA-D2 (ﬁg. 2A, lane 2).41 Transduction of putative
FA-D2 LCLs with FANCD2 cDNA with use of the retroviral
vector S11FD2IN restored FANCD2 expression and func-
tion, as reﬂected by the emergence of both FANCD2 iso-
forms (FANCD2-S and -L) (ﬁg. 2A, lane 3); simultaneously,
the MMC sensitivity of transduced cells returned to nor-
mal control-cell levels, as evidenced by the reduction of
G2 phase cell–cycle fractions (ﬁg. 2A, lane 1, and ﬁg. 2B,
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Table 4. FANCD2 Exon Primers
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
Figure 2. Delineation of FA-D2. A, Assignment to group FA-D2
on the basis of the absence of either FANCD2 band on immunoblots
after exposure of the patients’ cells to MMC, here shown for an
LCL from patient 6 (lane 2). Transduction with FANCD2 cDNA with
use of S11FD2IN restores both isoforms of FANCD2—S and L (lane
3)—similar to a nontransduced normal control (lane 1). Trans-
duction with FANCA cDNA in the same vector fails to show such
restoration (lane 4). B, Assignment to group FA-D2 on the basis
of cell-cycle analysis. After exposure to MMC, the LCL of the same
patient shows pronounced G2-phase arrest (56.6%) (lane 2;
Hoechst 33342 staining). Transduction with FANCD2 cDNA by use
of S11FD2IN reduces the G2 phase to normal (14.9%) (lane 3,
arrow), similar to the nontransduced normal control (16.6%) (lane
1). Transduction with FANCA cDNA in the same vector fails to
reverse the G2-phase arrest (53.1%) (lane 4). Panels C and D are
analogous to panels A and B and show complementation with
cultured ﬁbroblasts from patient 10; staining in panel D was with
4’,6-diamidino-2-phenylindole (DAPI). G2-phase proportions in
panel D are 20.3% (lane 1, control), 61.3% (lane 2, nontransduced
FA), 19.9% (lane 3, FANCD2-transduced FA), and 58.5% (lane 4,
FANCA-transduced FA). RAD50 [MIM 604040] was used as the load-
ing control in panels A and C. WTpwild type.
Table 5. FANCD2 Mutation-Speciﬁc Primers
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
lanes 1 and 3). Transduction of D2 LCLs with GFP or
FANCA resulted in neither the restoration of either FANCD2
isoform nor a normalization of G2 phase arrest, as ex-
empliﬁed for FANCA with use of S11FAIN, as shown in
ﬁgure 2A and 2B, lanes 4. In cases with suspected hema-
topoietic mosaicism, cultured ﬁbroblasts were assayed us-
ing a corresponding strategy (ﬁg. 2C and 2D). As shown
in table 7, only a minority of patients were assigned to
group FA-D2 by primary mutation analysis. This group
includes four affected siblings of four different index pa-
tients and an unrelated deceased patient with only DNA
available.
In the North American IFAR collection, of 630 classiﬁed
patients with FA, 7 (patients 19–25) were fully informative
clinically and were included in the present cohort; an-
other (patient 32) is among the four additional patients.
Results of immunoblotting data alone suggested that 10
more IFAR patients belonged to the FA-D2 group, for a
maximum estimate of 18 FA-D2 subjects in the IFAR group
of 630. Among the patients referred to the two German
laboratories, 15 of 243 patients with FA were assigned to
complementation group FA-D2. The latter ﬁgures suggest
that the proportion of patients who meet criteria for
complementation group D2 may be higher than reported
elsewhere.2,24,25
Clinical Data for FA-D2 Patients
Including, where appropriate, information fromaprenatal
case (number 19), phenotypic details in the present cohort
of 29 FA-D2 patients with adequate clinical information
are shown in tables 8 and 9. With the exception of two
families (those of patients 19 and 22), there was no general
tendency for increased rates of spontaneous abortions in
this study. Among the 28 fully informative FA-D2patients,
there was only a single malignancy observed (acute mye-
logenous leukemia [AML] in patient 1), and there was no
apparent overrepresentation of malignancies in the par-
ents or grandparents of the FA-D2 patients in our cohort.
The median age at diagnosis of these FA-D2 patients was
4 years and 5 mo ( ). When the fetal case (numbernp 29
19) and ﬁve mosaic patients (patients 3, 14, 15, 25, and
26) were excluded, the median age at transfusion depen-
dency was 10 years and 10mo ( ). Figure 3 comparesnp 23
the progressive hematological course and the outcome of
our group of FA-D2 patients with that reported elsewhere
for 754 North American IFAR patients.42 BMF in our D2
group ( ) occurred at an earlier age (median for FA-np 23
D2 patients was 2.4 years vs. 6 years and 7 mo for IFAR;
) (ﬁg. 3A), and the period from BMF to HSCT wasPp .001
shorter (median age at HSCT for FA-D2 patients [ ]np 9
was 5 years and 6 mo vs. 11 years and 4 mo for IFAR
[ ]; ) (ﬁg. 3B). Age at HSCT for our FA-D2np 218 P ! .08
patients was earlier than in the IFAR patients of combined
groups (median age for FA-D2 patients was 10 years and
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Table 6. Microsatellite Primers
STR
Genomic
Position
(Mb)
Primer Sequence
(5′r3′)
Sense Antisense
D3S1597 9.34 AGTACAAATACACACAAATGTCTC CAATTCGCAAATCGTTCATTGCT
D3S1038 10.49 AAAGGGGTTCAGGAAACCTG CCCTCCAGTAAGAGGCTTCCTAG
D3S3611 10.53 GCTACCTCTGCTGAGCATATTC CACATAGCAAGACTGTTGGGGGC
D3S1675 10.64 GGATAGATGGATGAATGGATGGC CCTCTCTAACTACCAATTCATCCA
Table 7. Laboratory Diagnostic Data for
the Cohort of 29 FA-D2 Patients
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
11 mo vs. 27 years and 11 mo for IFAR; ) (ﬁg. 3C).P ! .01
Of 23 FA-D2 patients, 9 patients of our cohort received
HSCT. Kaplan-Meier estimates (ﬁg. 3D) suggest that our
FA-D2 patients ( ) may have a shorter life span thannp 23
the IFAR patients overall, since their survival curve falls
below that of the IFAR patients after age 9 years; however,
the difference of median survival (11 years and 4 mo for
FA-D2 patients vs. 24 years and 3 mo for IFAR) was not
signiﬁcant, because the number of nonmosaic FA-D2 pa-
tients (two) of our cohort who reached adulthood was too
low for statistical support.
FANCD2 and the FANCD2 Pseudogenes
BLAT searches (Human BLAT Search) identiﬁed two pseu-
dogene regions: FANCD2-P1 spanning 16 kb, located ∼24
kb upstream of FANCD2, and FANCD2-P2 spanning 31.9
kb, located ∼1.76 Mb downstream of FANCD2 (ﬁg. 4A).
P1 and P2 are in the same orientation as the functional
gene. They are characterized by high sequence homology
with certain FANCD2 exons and have retained ordered
succession of their exon/intron equivalents, compared
with the functional gene. On the other hand, the exon
replicas of FANCD2-P1 and FANCD2-P2 have acquired nu-
merous deletions and insertions. Striking sequence simi-
larity of the D2 pseudogenes extends into some FANCD2
introns, particularly in the regions of IVS21-IVS26. Thus,
P1 and P2 reveal recognizable patterns of conserved gene
structure (ﬁg. 4B). FANCD2-P1 is roughly a copy of the
front portion of FANCD2, including, with intermittent
gaps, the region of exons 1–18 (homology with FANCD2
exons 1 and 12–16 and the 3′ portion of exon 18). The
region upstream of FANCD2-P1 shares homology with the
putative FANCD2 promoter predicted within theCpG-rich
region of ∼800 bp upstream of the start codon of the func-
tional gene.60 The corresponding region upstream of P1 is
interrupted by an AluY element (RepeatMasker). FANCD2-
P2 is an approximate match of the middle portion of
FANCD2. Including gaps, it spans the region of exons 12–
28 (homology with FANCD2 exons 12–14 and 17–28).
Mutations in FANCD2
Unique ampliﬁcation of the functional FANCD2 gene
was achieved using primers that exclude pseudogene se-
quences. In FANCD2 regions sharing extensive homology
with FANCD2-P1 and -P2, seven superamplicons (ﬁg. 4C)
were used for genomic mutation screens. Studies at the
RNA level were implemented to guide the genomic anal-
yses. All identiﬁed mutations and their predicted conse-
quences at the protein level are compiled in table 10. The
distribution of the mutations among the individual pa-
tients is shown in table 7.
Mutations Affecting Pre-mRNA Splicing
In peripheral-blood lymphocytes (PBLs), LCLs, and cul-
tured ﬁbroblasts from unaffected controls, two species of
FANCD2 cDNAs were consistently detected by sequence
analysis of the regions corresponding to exon 22 (ﬁg. 5A
and 5B) and exons 15–17 (data not shown). This obser-
vation suggests low-level skipping of these exons, consis-
tent with FANCD2 RNA being subject to alternative splic-
ing. mRNA stabilization via CHX treatments of cultured
cells resulted in a relative increase of the alternatively
splicedmRNA species (ﬁg. 5A and 5C), implying instability
of the alternatively spliced FANCD2 mRNAs. On genomic
sequencing, alternative splicing of exon 22 was not as-
sociated with any mutation or variant in exon 22 or the
adjacent intronic regions in 25 controls.
Without CHX treatments, cell lines from patients 2, 8,
9, 10, 14, 15, and 20 in our cohort displayed almost equal
levels of exon 22 skipping and retention (ﬁg. 5A and 5D).
Patients 9 and 10, with balanced levels of exon 22 skipping
and retention, were compound heterozygous carriers of
the mutation c.1948-16TrG. A different base substitution
preceding exon 22, c.1948-6CrA, was present on one al-
lele of the compound-heterozygous patients 2, 8, 14, 15,
and 20, likewise resulting in similar levels of exon 22 skip-
ping and retention. Both mutations—c.1948-16TrG and
1948-6CrA—are predicted to disrupt the splice-acceptor
recognition in intron 21 suggested by impaired scores of
the 3′ splice site relative to the wild type (see, e.g., table
11). Both result in skipping of exon 22.
Three apparently unrelated patients (patients 6, 12, and
30) showed balanced levels of skipping and retention of
exon 5 due to heterozygous insertional mutagenesis by an
Alu element between positions c.274–57 and c.274–56
into an AT-rich target sequence in IVS4. Integration site,
type, length, and orientation of theAlu and the duplicated
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Table 8. Clinical Phenotype of the Cohort of FA-D2 Patients
Malformation
No. of
Affected/
Totala
Frequency
(%)
Symptom:
Microcephaly 25/28 89
(Intrauterine) growth retardation 25/29 86
Anomalies of skin pigmentation 21/28 75
Radial-ray defects 21/29 72
Microphthalmia 17/28 61
Renal anomalies 10/28 36
Malformations of the external ear 9/28 32
Brain anomalies 9/29 31
Including hydrocephalus 5/29 17
Psychomotor retardationb 8/28 29
Hypogonadism/genital anomalies 7/28 25
Hip dysplasia/dislocation 6/28 21
Heart anomalies 4/28 14
Malformations of the gastrointestinal tract 4/28 14
Distinct syndromic association:
Michelin-tire baby syndrome (MIM 156610) 2/28 7
VACTERL-like association (MIM 192350) 1/28 4
Holoprosencephaly (MIM 236100) 1/28 4
Kartagener syndrome (MIM 244400) 1/28 4
a A prenatal case (number 19) was partially informative. Pertinent information
was used where applicable.
b Including attention-deﬁcit/hyperactivity disorder.
Table 9. Clinical Diagnostic Data for the
Cohort of 29 FA-D2 Patients
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
FANCD2 intron sequence were identical in all three pa-
tients. We did not detect any such Alu insertions in 300
unaffected control alleles.
Aberrant splicing of exons 4, 5, 10, 13, 15–17, 28, and
37 was observed in other patients also (analysis of the
regulatory splec sequences by ESEﬁnder and Rescue-ESE).
Patients 28 and 29 showed skipping of exon 4 caused by
a base substitution in the preceding canonical splice-ac-
ceptor site (c.206-2ArT). Patients 26 and 27 had a base
substitution in exon 5 (c.376ArG) abrogating the down-
stream splice donor. This change led to the inclusion of
13 bp of IVS5 into the transcript by activating a cryptic
5′ splice site in intron 5 (r.377_378ins13) also reported
elsewhere.26 Patient 18 showed skipping of exon 10 due
a base substitution in the upstream splice acceptor (c.696-
2ArT). Exon 10 skipping was observed in patient 31, who
had a substitution of the second-to-the-last base of exon
10 (c.782ArT). In patient 8, we detected a splice-acceptor
mutation upstream of exon 13 (c.990-1GrA). This change
results in the activation of a cryptic splice acceptor 8 bp
downstream and the exclusion of the corresponding se-
quence from the mature mRNA. A 2-bp deletion in exon
16 (c.1321_1322delAG) in patient 18 causes skipping of
exons 15–17. In that case, aberrant splicing occurs in the
same position as low-grade alternative splicing in normal
controls, but at heterozygous levels. Patients 10 and 22
showed inclusion of a 27-bp sequence of intron 28 into
mRNA because of a splice-donor mutation (c.27151GrA)
and the use of a cryptic splice-donor downstream. Patient
11 had a base substitution in exon 37 (c.3707GrA), re-
ported elsewhere,26 that abrogates the normal splice ac-
ceptor 25 bp upstream and activates a cryptic site 19 bp
downstream of the mutation, resulting in skipping of 44
bp. Interestingly, an adjacent base substitution(c.3706CrA)
in patient 32 generates a new splice acceptor that is used
instead of the normal one 23 bp upstream, leading to
skipping of the 24 nt in between. With the exception of
those of patient 1, all of these splicing aberrations were
due to heterozygous mutations. Patient 1 showed homo-
zygous exonization of an IVS9 fragment because of a mu-
tation in intron 9 (c.696-121CrG), which activates cryptic
splice sites. Predicted scores and consequences of some of
these splice mutations are computed in tables 11 and 12.
Apart from 1321_1322delAG, which causes skipping of
exons 15–17, all mutations affecting splicing in the pa-
tients in this study result in frameshifts and subsequent
premature termination of translation. More than half—
that is, 30 of 58 mutated alleles of the 29 clinically in-
formative FA-D2 patients, or 34 of all 66 alleles—were
splicing mutations, which makes that the most prevalent
type of mutation.
Other Mutations
There were ﬁve different heterozygous nonsense muta-
tions in nine patients from six families (c.757CrT in sib-
lings 23 and 24, c.1092GrA in patient 7, c.2404CrT in
patient 21, c.2775_2776CCrTT in siblings 14 and 15, and
c.3803GrA in patient 6 and siblings 26 and 27) (tables 7
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Table 10. Identiﬁed FANCD2 Mutations and Their Effects
Location and Patient No(s).
Mutationa Consequencea
Genomic DNA RNA Protein
Exon 2:
32 c.2TrC r.2TrC Failure of normal translation
initiation
Intron 3:
28 and 29 c.206-2ArT (IVS3-2 ArT) r.206_273del68 (exon 4 skipping) p.A69DfsX7
Intron 4:
6, 12, and 30 c.274-57_-56insinvAluYb8nt36_319 dup c.274-69_57b r.274_377del104 (exon 5 skipping) p.I92YfsX7
Exon 5:
26 and 27 c.376ArG r.376ArGr.377_378ins13 (aberrant splicing) p.S126RfsX12
Exon 9:
19 c.692TrG r.692TrG p.L231R
Intron 9:
1 c.696-121CrG (IVS9-12 1CrG) r.6951619_696-126ins34 (exonization) p.S232insQNNFX
18 c.696-2ArT (IVS9-2 ArT) r.696_783del88 (exon 10 skipping) p.S232RfsX6
Exon 10:
23 and 24 c.757CrT r.757CrT p.R253X
31 and 33 c.782ArT r.696_783del88 (exon 10 skipping) p.S232RfsX6
Exon 11:
9 c.810_812delGTC r.810_812delGTC p.S271del
Exon 12:
7 c.904CrT r.904CrT p.R302W
Intron 12:
8 c.990-1GrA (IVS12-1 GrA) r.990del8 (aberrant splicing) p.S330RfsX16
Exon 13:
7 c.1092GrA r.1092GrA p.W364X
Intron 14:
33 g.13377_17458dup4082 (duplication, including exons 11–14) r.784_1134dup (duplication of 351 nt in-frame) p.262_378dup (duplication of 117 aa)
Exon 16:
18 c.1321_1322delAG r.1135_1545del411 (exon 15–17 skipping) p.V379_K515del
23 and 24 c.1367TrG r.1367TrG p.L456R
31 c.1370TrC r.1370TrC p.L457P
Exon 17:
28, 29 g.22875_23333del459 (c.1414-71_c.1545256del459) r.1414_1545del132 p.E472_K515del
Intron 21:
3, 4, 5, 9, 10, 13, and 25 c.1948-16TrG (IVS21-16 TrG) r.1948_2021del74 (exon 22 skipping) p.E650X
2, 8, 14, 15, and 20 c.1948-6CrA (IVS21-6 CrA) r.1948_2021del74 (exon 22 skipping) p.E650X
Exon 26:
21 c.2404CrT r.2404CrT p.Q802X
16, 17, 19, 21, 22, and 30 c.2444GrA r.2444GrA p.R815Q
Exon 28:
20 c.2660delA r.2660delA p.E888RfsX16
Intron 28:
10 and 22 c.27151GrA (IVS281GrA) r.2715_2716ins27 (aberrant splicing) p.E906LfsX4
Exon 29:
14 and 15 c. 2775_2776CCrTT r. 2775_2776CCrTT p.R926X
11 c.2835dupC r.2835dupC p.D947RfsX3
Exon 34:
12 c.3453_3456delCAAA r.3453_3456delCAAA p.N1151KfsX46
Exon 36:
2 c.3599delT r.3599delT p.I1200KfsX12
Exon 37:
32 c.3706CrA r.3684_3707del24 (aberrant splicing) p.R1228S_F1235del
11 c.3707GrA r.3684_3727del44 (aberrant splicing) p.H1229EfsX7
Exon 38:
6, 26, and 27 c.3803GrA r.3803GrA p.W1268X
a Nomenclature is according to the Human Genome Variation Society.
b This Alu was identical to the evolutionary young subfamily Yb8.43,44 It was lacking its annotated nucleotides 1–35, had integrated in reverse orientation (with its poly-A tail toward the 5′
end of FANCD2), and had duplicated the 13-nt sequence c.274–69 to c.274–57 of FANCD2 IVS4, such that this duplicated sequence ﬂanked the Alu repeat on both sides. Altogether, the insertion
length was 298 bp.
and 10). In addition, we detected ﬁve different missense
mutations in 11 patients from nine families (c.692TrG in
patient 19; c.904CrT in patient 7, identical to a mutation
reported elsewhere26; c.1367TrG in siblings 23 and 24;
c.1370TrC in patient 31; and c.2444GrA in siblings 16
and 17 and patients 19, 21, 22, and 30). These amino acid
substitutions were classiﬁed as missense mutations be-
cause of their absence from unaffected controls, their ab-
sence from FA-D2 patients of our cohort with other bial-
lelic mutations, and their occurrence at evolutionarily
conserved residues (ClustalW; ExPASy). Missense muta-
tions were either compound heterozygous in combination
with other types of FANCD2 mutations or were homo-
zygous in consanguineous families. Three unrelated pa-
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Figure 3. Clinical course of 23 fully informative, nonmosaic FA-D2 patients in this study. A, The cumulative incidence of BMF of the
FA-D2 patients in the present study (FA-D2) precedes that of all patients with FA in the IFAR42 ( ). B, The period from BMF toPp .001
HSCT, which was shorter in the patients of the present study than in those of the IFAR42 (trending, ). C, Cumulative incidenceP ! .08
of HSCT of the FA-D2 patients in our study, which likewise antedates that of all patients in the IFAR42 ( ). D, Kaplan-Meier curvesP ! .01
of survival, which suggest higher death rates of the FA-D2 patients than of all patients in the IFAR aged 110 years.
tients had small deletions (c.2660delA in patient 20,
c.3453_3456delCAAA in patient 12, and c.3599delT in
patient 2) resulting in frameshifts. Another small dele-
tion was in frame and affected a single codon (c.810_
812delGTC in patient 9). There was only a single small
frameshift duplication (c.2835dupC in patient 11). A large
genomic deletion (g.22875_23333del459) spanning the
entire exon 17 (similar to a mutation reported elsewhere
without deﬁned breakpoints26) and the adjacent 71 bp of
intron 16 and 256 bp of intron 17 was found in sibling
pair 28 and 29. This deletion resulted in a net loss of 41
aa. A large genomic duplication in patient 33 included
exons 11–14 and resulted in the insertion of 132 aa. Both
gross gene rearrangements retained the reading frame. In
all of our patients, nonsense mutations, deletions, and
insertions affected exclusively single alleles in combina-
tion with splice or missense mutations. A unique case was
a compound heterozygous start codon mutation (c.2TrC)
in patient 32.
Figure 6 illustrates the distribution of FANCD2 muta-
tions that were identiﬁed in this study, including those of
four FA-D2 patients who were reported elsewhere.26,27
Ethnic Associations and Shared Alleles
Relatively severe birth defects and early hematological on-
set were observed in three patients (4, 5, and 13) whowere
homozygous for the splice mutation c.1948-16TrG with
exon 22 skipping. These three patients and two other ho-
mozygotes with reverse mosaicism in the hematopoietic
system (patients 3 and 25) were all from four consan-
guineous Turkish families. Of two other FA-D2 patients
who were compound heterozygotes for this mutation, one
was also of Turkish origin; the other came from the eastern
Czech Republic. The splice mutation c.1948-6CrA, like-
wise leading to exon 22 skipping, was detected in ﬁve
patients (2, 8, 14, 15, and 20), including two sisters (pa-
tients 14 and 15). These patients came from three families
in northern Germany and an American family of German
ancestry (patient 20). They presented with intermediate
phenotypic and hematological severity. Relatively mild
birth defects and a protracted hematological course into
adulthood was observed in two siblings, from a consan-
guineous Spanish family (patients 16 and 17), with the
homozygous missense substitution c.2444GrA. Of four
compound heterozygotes for this mutation with mild dis-
ease manifestations, one hadmixed ethnicity (patient 19),
one was Hispanic American (patient 21), one had Sicilian
ancestry (patient 22), and another had Spanish and Por-
tuguese ancestry (patient 30). An allele with the insertion
of an AluYb8 element was found in compound heterozy-
gous patients of German (patient 6), Danish (patient 12),
and Spanish/Portuguese (patient 30) descent. No othermu-
tations occurred in more than two families.
On haplotype analysis using markers ﬂanking FANCD2,
all patients homozygous for the intron 21 mutation de-
tected in the Turkish population were homozygous for
markers D3S1597, D3S1938, D3S3611, and D3S1675. The
resulting haplotype was shared, in a heterozygous state,
with the nonconsanguineous compound heterozygous
Turkish patient (patient 10). The Czech patient (patient
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Figure 4. Topography of FANCD2, its pseudogenes, and the superamplicons. A, The two pseudogenes—FANCD2-P1 and FANCD2-P2—
located upstream and downstream, respectively, of the functional FANCD2 gene. All three have the same orientation. The scale denotes
Mb on chromosome 3. B, FANCD2 exons and their pseudogene equivalents, connected by dashed lines, indicating percentages of nucleotide
identity. Homology also extends into many introns nearby, as indicated by the boxes beyond and below the active gene. C, Graphic
presentation of the positions and sizes of 7 superamplicons relative to the active gene shown in panel B. These amplicons represent
FANCD2 exon-exon or exon-intron regions. Unique primer-binding sites ensure speciﬁc ampliﬁcation.
9) with the same mutation had a different haplotype. Lack
of homozygotes for the intron 21 mutation prevalent in
the German population (c.1948-6CrA; patients 2, 8, 14,
15, and 20) and unavailability of patients’ parents pre-
cluded construction of a mutation-associated haplotype.
However, all patients with this mutation had one or two
identical marker(s) on at least one side of their mutated
FANCD2 gene. This ﬁnding suggests that c.1948-6CrA is
an old mutation, with erosion of an ancient haplotype.
The consanguineous siblings (patients 16 and 17) homo-
zygous for the mutation prevalent in Spanish or southern
European populations (c.2444GrA) were also homozy-
gous for the set of markers used. Of their common hap-
lotype, the microsatellite markers adjacent to FANCD2
were shared with a Hispanic patient (patient 21), a patient
with Sicilian ancestry (patient 22), and a patient of Span-
ish/Portuguese descent (patient 30), all compound het-
erozygotes for this mutation. Additional support for a con-
served haplotype came from linkage disequilibrium. All
of the patients homo- or heterozygous for the mutation
c.2444GrA were also homo- or heterozygous for the poly-
morphism c.2702GrT (p.G901V). Sequence analysis of
the parents indicated that both substitutions were on the
same allele. A single patient (patient 19)with themutation
c.2444GrA shared neither the haplotype nor the poly-
morphism c.2702GrT. Apart from c.2702GrT, which was
also observed without association with the mutation
c.2444GrA, the only new FANCD2 polymorphisms de-
tected in our study were c.3978CrT (synonymous base
substitution, exon 41) and c.4478ArG (3′ UTR, according
to GenBank accession number NM_033084, or intron 43,
according to accession number AF340183). All others have
been reported elsewhere.26 Despite clear ethnic association
of the patients with the insertion of an AluYb8 element
in intron 4, two of these patients (6 and 12) shared all of
the four markers studied. Patient 30, with the same mu-
tation, had retained a single identical marker adjacent to
FANCD2. A base substitution in the Alu sequence, 260GrA,
present in all three cases but in !10% of complete AluYb8
elements in the human genome (Human BLAT Search)
further suggests that the Alu insertion goes back to a single
event and is an ancient rather than a recurrent mutation.
Reverse Mosaicism
Among the 28 fully informative FA-D2 patients in this
study (excluding fetal case number 19), ﬁve (patients 3,
14, 15, 25, and 26) developed reverse mosaicism in the
hematopoietic system.Mosaic patients were recognizedby
the fact that they had levels of both FANCD2-S and -L in
protein from LCLs that were comparable to those of un-
affected controls (ﬁg. 7A). They also had low chromosome
breakage rates in blood and blood-derived LCLs (table 7),
and they had lost the typical G2-phase arrest of their lym-
phocytes after exposure to MMC (ﬁg. 7C). Nonetheless,
these patients displayed the characteristic clinical FA phe-
notype. Their cultured ﬁbroblasts failed to show either
FANCD2 isoform on standard immunoblots (ﬁg. 7B). They
were sensitive to MMC, as indicated by elevated chromo-
some breakage and G2-phase arrest (ﬁg. 7C). Molecular
studies conﬁrmed these ﬁndings. Two patients with het-
erozygous base substitutions in the coding sequence, re-
sulting in a nonsense (patient 14) and a splice (patient 26)
mutation, showed reversion to the respective wild-type
bases in primary blood cells and LCLs. The mechanism of
these reversions is not clear and could involve back mu-
tation, recombination with loss of heterozygosity, or re-
combination with gene conversion. Intragenic mitotic
crossover is the likely but not proven mechanism of mo-
saicism in the sibling of patient 14 (patient 15) who had
retained her dinucleotide substitution in her peripheral-
blood cells. Two patients (3 and 25) with the c.1948-
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Figure 5. Exon 22 splicing. A, Schematic depiction of the splicing
patterns resulting from exon 22 retention or skipping. B, cDNA
sequencing in an LCL from a normal control (CON), showing pre-
dominance of exon 22 sequence following that of exon 21 but also
low levels of underlying sequence readable as exon 23. C, Treatment
of the same LCL from a normal control with CHX for 4 h before
cDNA synthesis, which increases the relative level of sequence with
exon 22 skipping. D, cDNA sequencing in an LCL from a compound
heterozygote (HET) for splice-acceptor mutation in intron 21,
c.1948-16TrG (patient 9), which shows comparable levels of in-
clusion and exclusion of exon 22 sequence following that of exon
21. Expexon; WTpwild type.
Table 11. FANCD2 3′ Splice-Acceptor Calculations
Exon/Intron and
Designation Sequence
MaxEntScan
Scorea
4:
Consensus ctcttcttttttctgcatagCTG 9.12
c.206-2ArT ctcttcttttttctgcattgCTG .76
10:
Consensus tctttttctaccattcacagTGA 7.39
c.696-2ArT tctttttctaccattcactgTGA .97
13:
Consensus ttcctctctgctacttgtagTTC 6.19
c.990-1GrA ttcctctctgctacttgtatTTC 2.56
22:
Consensus tgtttgtttgcttcctgaagGAA 6.43
c.1948-16TrG tgttggtttgcttcctgaagGAA 5.58
c.1948-6CrA tgtttgtttgcttcatgaagGAA 4.51
37:
Consensus ACTTTTGTTGTTTTCTTCCGTGT 2.10
c.3706CrA ACTTTTGTTGTTTTCTTCAGTGT 10.14
a MaxEntScan::score3ss for human splice sites.
16TrG splice mutation had different second-site muta-
tions nearby. The compensatorymutation of patient 3was
c.1954GrA (p.V652I), detected in blood, bone marrow,
and an LCL. The compensatory mutation of patient 25
was c.1953GrT (p.W651C), detected in blood. c.1954GrA
restored exon 22 retention correctly. c.1953GrT cDNA
was not available. Clinically, three of ﬁve mosaic patients
(3, 14, and 15) in the present cohort experienced a mild
or protracted hematological course. The other two of ﬁve
patients (patients 25 and 26) had no apparent beneﬁt from
their mosaicism; one of them required relatively early
HSCT, and the other died of intracranial hemorrhage (ta-
ble 9). The rate of 17% mosaic FA-D2 patients in our study
is within the 15%46 to 20%47 or 25%48 range reported for
other complementation groups. With a rate comparable
to FANCA, FANCD2 appears to be another FA gene partic-
ularly prone to reverse mosaicism.
Residual FANCD2 Protein
cDNA sequencing of LCLs of patients 3, 4, 5, and 13
showed nearly complete exon 22 skipping. However, we
consistently observed a small amount of correctly spliced
mRNA retaining exon 22 (ﬁg. 8A; compare with ﬁg. 5A).
Genomic sequencing identiﬁed homozygosity of these pa-
tients for the common underlyingmutation, the base sub-
stitution c.1948-16TrG in IVS21. Homozygosity for this
mutation was also observed in the deceased patient 25
with no cDNA available. All of these patients were prod-
ucts of consanguineous matings. In all LCLs that were
homozygous for the above splicingmutation,wewere able
to demonstrate minute amounts of FANCD2 protein. A
more surprising ﬁnding, however, was the presence of re-
sidual FANCD2 protein in PBLs and LCLs of every tested
FA-D2 patient. Detection of residual protein required over-
exposure of FANCD2 immunoblots (ﬁg. 8B). Unlike stan-
dard exposures that revealed no FANCD2 bands in most
of the FA-D2 cell lines (see, e.g., ﬁg. 2), both FANCD2-S
and FANCD2-L bands were detected when ﬁlms were ex-
posed overnight. As the study progressed, it became evi-
dent that the cell lines initially detected with residual pro-
tein were those with the highest levels. When we system-
atically re-examined all of our FA-D2 lines, all 21 LCLs
available from our 29 fully informative FA-D2patients had
minute but unequivocal amounts of residual protein (table
7). This was also true for CD3/CD28/IL-2–stimulated PBL
cultures from patient 13. Patients 4, 17, and 19 with no
available LCLs remained untested. In contrast, our mosaic
patients displayed levels of FANCD2 protein in the control
range. They had normal chromosome-breakage rates and
lacked G2-phase arrest, whereas the nonmosaic patients
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Table 12. FANCD2 Splice-Donor Calculations
Exon/Intron and
Designation Sequence
Score
(Spliceﬁnder) Difference Result
5:
Consensus CAGgtgtggag LC4 12FF3F2F
c.376ArG CGGgtgtggag LC2 2F8FF3F2 Large Malfunction
Cryptic splice donor GAGgcatggaaa HC1 F12F3F2F Gain of function
9:
Consensus acggtaactta LC4 FF12F2FF
c.696-121CrG ACGgtaagtta HC3 FF17FF Large Gain of function
10:
Consensus AAGgtagaaaa LC4 F12FFF2F
c.782ArT ATGgtagaaaa LC3 FF10FFF2F Small Malfunction
28:
Consensus AAGgtattgga LC4 F12FFFFF
c.27151GrA AAGatattgga No score Large Malfunction
Cryptic splice donor AAGgtttgtgaa LC4 F10FF5FF Gain of function
a Mutation-activated cryptic splice donor; calculation available only for the consensus dinucle-
otide gt.
Figure 6. Positions and identity of mutations detected in FANCD2. Mutations identiﬁed in the present study are shown above, mutations
reported elsewhere24,45 are indicated below the schematic display of FANCD2 cDNA. Blackened squares () represent mutations resulting
in aberrant splicing patterns, blackened circles (•) represent nonsense mutations, unblackened circles () represent missense mutations,
blackened triangles (H17009) represent frameshift deletions or duplications, and unblackened triangles (D) represent in-frame deletions or
duplications. Missense mutations are depicted above or below the other mutations and are underlined. Superscript a at the right upper
corner of a symbol denotes homozygous occurrence (2 alleles); superscript b denotes an affected sibling (relationship bias). Mutation
3707GrA was originally reported as a missense mutation,26 whereas we characterized it as a splicing mutation.
had high chromosome breakage and G2 arrest. We there-
fore consider it unlikely that undetected mosaicism ac-
counts for the presence of residual protein in the remain-
der of our patients. In support of this conclusion, we were
able to detect residual protein, including both -S and -L
bands, in ﬁbroblasts from patients 3, 14, and 26 when the
blot of ﬁgure 7B was overexposed (data not shown). Den-
sitometry suggested reductions of residual FANCD2 pro-
tein on the order of 1 of 100 to 1 of 1,000 relative to wild
type, with the degree of expression differing greatly among
individual LCLs (ﬁg. 8B). FA-D2 LCLs with the highest
levels of residual FANCD2 were used to examine its char-
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Figure 7. Reverse mosaicism. Blood-derived cells from FA-D2 pa-
tients with reverse mosaicism of the hematopoietic system (pa-
tients 3 and 26, LCLs; patient 14, stimulated PBL; panel A, lanes
2, 3, and 4) reveal both FANCD2 bands at levels similar to a random
normal control (lane 1) after exposure to MMC. In contrast, neither
FANCD2 band was present in ﬁbroblasts from the same patients,
but only in the control (B). RAD50 was used as loading control in
panels A and B. The LCLs and PBL used in panel A fail to show
G2-phase arrest on ﬂow cytometric cell cycle distributions in re-
sponse to MMC (panel C) (black histograms indicate DAPI stain;
control (CON), 8.0% G2; patient 3, 8.8% G2; patient 14, 8.8% G2;
patient 26, 10.4% G2), whereas the corresponding cultured FA-D2
ﬁbroblasts retain high G2-phase accumulations, which is again in
contrast to the non-FA control (superimposed gray histograms; CON,
22.6% G2; patient 3, 53.2% G2; patient 14, 56.0% G2; patient
26, 54.8% G2). PBLs in panel A were stimulated with anti-CD3,
anti-CD28, and Il-2 and, in panel B, with PHA.
acteristics on overexposed blots. The intensity of the
FANCD2-L band increased as a function of the concen-
tration of the DNA crosslinking agent (ﬁg. 8C) and the
period of treatment (not shown). This time and concen-
tration dependency suggests genuine biochemical activity
of the residual FANCD2 protein, implying that most, if
not all, cases of FA-D2 result from functionally hypo-
morphic mutations.
Discussion
Our results suggest that FA-D2 is a more frequent FA com-
plementation group than previously reported, apparently
inﬂuenced by the high proportion of patients from spe-
ciﬁc ethnic groups in the present study. 2,24,25 The relatively
large proportion of FA-D2 patients with Turkish ancestry
in the present study appears to be due to a founder effect
for the FANCD2 mutation c.1948-16TrG among individ-
uals of Turkish origin. This is similar to the disparity in
the frequency of FA-C patients in the IFAR database com-
pared with the European FA population. The proportion
of FA-C patients in the IFAR is 15%,49 compared with only
10% in the European data set.2 This is due to the relatively
high frequency of Ashkenazi Jewish patients with FA in
the IFAR who have the prevalent FANCCmutation c.456
4ArG (formerly referred to as “IVS44ArG”),33 compris-
ing 7.5% of all IFAR patients and 50% of these FA-C pa-
tients. On the basis of our present data, we estimate that
∼6% of patients with FA belong to complementation
group D2. This estimate is supported by recent studies
with ﬁgures of 4 of 53 (∼7.5%),46 3 of 73 (∼4.1%),50 and
5%.49
The FA-D2 patients in our cohort displayed anomalies
and malformations typical of FA such that there were no
exceptional clinical features that had not been observed
elsewhere.51 However, it is remarkable that not a single
FA-D2 patient lacked phenotypicalmanifestations,whereas
the proportion of patients with FA without anomalies and
malformations is generally estimated to be as high as
30%.24 Growth retardation was present in 86% of the pre-
sent cohort, substantially higher than the 58%52 and
63%24 reported. Microcephaly was present in 89% of the
FA-D2 cases; in contrast, Faivre et al.52 found anomalies
of the head in only 56%. Anomalies of skin pigmentation
were present in 75% of our FA-D2 cohort, compared with
71% and 64% reported elsewhere.24,52 Of our FA-D2 pa-
tients, 72% had radial-ray defects, in contrast to only
47%52 or 49.1%51 of all patients with FA. Of the patients
in the present study, 61% had microphthalmia, whereas
38% has been the reported percentage in other patients
with FA.24 As with these rather common phenotypic al-
terations, FA-D2 patients also showed higher rates of rare
FA features, such as psychomotor retardation and hyper-
activity/attention-deﬁcit disorder. Psychomotor retarda-
tion was present in 29% of our FA-D2 cohort versus 12%
or 10% such individuals in other studies.24,52 A third of
our FA-D2 patients had anomalies of the brain, whereas
other studies report such alterations on the order of
4.5%,52 7.7%,51 and 8%24 of their patients with FA. Of
our FA-D2 patients with brain anomalies, 17% had hy-
drocephalus, in contrast to 4.6% reported elsewhere.51
Since several laboratories contributed to the present study
and since all of our FA-D2 patients came from groups of
patients with previously unassigned FA, it is unlikely that
our rates reﬂect major biases. However, a more severe D2
phenotype has also been observed in Drosophila, compar-
ing Fancd2 and Fancl knock-down.23 Given the high fre-
quency of phenotypic alterations, it is not surprising that,
in 30% of our FA-D2 patients, the diagnosis of FA was
made by the time the patients were aged 2 years. The
median age at diagnosis in our cohort was 4.5 years, which
is considerably younger than for other patients with FA,
for whom the diagnosis is made in only 30% of patients
before onset of hematological manifestations at the me-
dian age of 7.6 years.53 In addition to an earlier median
age of hematological onset (i.e., BMF) in our patients with
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Figure 8. Residual FANCD2 protein. A, Exon 23 sequence following that of exon 21 (exon 22 exclusion, aberrant splicing), which
prevails in cDNA from homozygotes for the splice-acceptor mutation in intron 21, c.1948-16TrG, but, at low level, underlying sequence
is readable as exon 22 (exon inclusion). Depicted are results from patient 5. B, Blood-derived cells from nonmosaic FA-D2 patients
(exempliﬁed 13, 5, 1, 21, 2, 6, 11, and 28) show faint but conspicuous FANCD2 bands of both species in response to MMC exposure
exclusively on overexposed immunoblots, as indicated by the very intense FANCD2 signals of the normal controls (CON) (patient 13,
stimulated PBL; patients 5, 1, 21, 2, 6, 11, and 28, LCLs; loading control RAD50). The individual abundance of residual protein varies
considerably at low levels. C, LCLs were subjected to the indicated concentrations of hydroxyurea (HU) for 16 h. On an overexposed
blot, the FANCD2-L band of the residual protein in the LCL from patient 21 increases with the HU concentration in a dose-dependent
response. Normal control LCLs are distinctive by their prominent FANCD2 signals.
FA, there was a shorter median period between BMF and
HSCT, earlier HSCT, and a tendency toward shorter me-
dian survival than of all FA-affected patients listed in the
IFAR.42 Because of relatively small numbers and the rel-
ative deﬁcit of older patients in our cohort, statistical
signiﬁcance was not reached for all of these end points.
HSCT appears to be a rather frequent therapeutic option
in FA-D2 patients. In theory, however, deﬁcient ATM
[MIM 607585]/ATR [MIM 601215]–dependent phospho-
rylation of FANCD245,54,55 could involve additional toxicity
of conditioning regimens. Collectively, our data suggest
that FA-D2 patients represent a group with frequent but
typical congenital anomalies and malformations andwith
relatively early hematological manifestations, compared
with most other FA complementation groups.
Among the FA proteins, FANCD2 is unique, since the
presence of residual protein and the demonstration of its
activation can be accomplished in a single assay. In our
cohort, LCLs and PBLs from 21 fully informative, non-
mosaic study FA-D2 patients showed traces of residual
FANCD2 protein. Importantly, the residual protein always
consisted of both FANCD2 isoforms, and the typical time-
and dose-dependent induction of FANCD2-L was main-
tained, suggesting a preserved function. Differences in ex-
pression levels of residual FANCD2 between individual
LCLs might result from variations of conserved splice-site
recognition, in mRNA and protein stability, and, very
clearly, from differences in cell growth. FANCD2 is highly
expressed and monoubiquitinated in the S phase of the
cell cycle.10,56 The proportion of S-phase cells is a function
of cell growth, such that differences in cell proliferation
between individual cell lines account for the wide varia-
tion of FANCD2 protein levels. These differences render
any quantitative mutation-speciﬁc comparisons of resid-
ual FANCD2 protein levels close to impossible. The exis-
tence of residual protein has been described elsewhere for
other FA-D2 patients,9,26,27,46 but our study conﬁrms resid-
ual protein as a consistent and, in all likelihood, essential
feature of cells of FA-D2 patients. Somatic reversion as a
cause of residual protein levels could be excluded inmany
of the patients in this study, because the diagnosis of FA
in these patients was based on hypersensitivity to cross-
linking agents of their cells in vitro. It could be argued
that these LCLs might include very small, undetected
amounts of reverted cells and thus might actually repre-
sent low-proportion mosaics. However, reverse mosaicism
has been widely observed only at certain rates (!25%)
and not at the frequency at which we detected residual
FANCD2 protein. Moreover, reverted cells, once present,
tend to outgrow nonreverted FA cells rather rapidly, at
least in LCLs, which never occurred in our long-term
studies. Finally, detection of residual protein with both
FANCD2-S and -L bands in some of our FA-D2 ﬁbroblast
lines without the possibility of mosaicism strongly argues
908 The American Journal of Human Genetics Volume 80 May 2007 www.ajhg.org
in favor of residual protein and against somatic reversion.
Of note, the vast majority of our FA-D2 patients are ho-
mozygous or compound heterozygous for at least a mis-
sensemutation or a nucleotide substitution affecting splic-
ing without altering the canonical AG and GT dinucleo-
tides of splice sites. Missense mutations might lead only
to a partial degradation of FANCD2, whereas the other
type of mutations causing exon skipping or aberrant splic-
ing might compete against but not abrogate the original
splice site, guaranteeing a residual amount of FANCD2.
FANCD2 is targeted to chromatin after DNA damage-
dependent monoubiquitination. In this process, FANCE
binds to FANCD2, providing the critical bridge linking
FANCD2 to FANCC and the rest of the FA core complex.57
The binding site of FANCD2 for FANCE has not been de-
termined. Our data suggest that this binding site, in ad-
dition to K561 and apart from an intact FA nuclear core
complex, must be retained by mutated residual FANCD2
protein to become monoubiquitinated.
Despite a rather severe phenotype in most of the FA-
D2 patients, the vast majority of our FA-D2 patients were
found to carry leaky mutations, affecting merely splicing,
and displayed residual FANCD2 protein of both isotypes
in their cell lines. Splicing mutations have become an in-
creasingly successful target for experimental therapeutic
approaches. Modiﬁed and antisense oligonucleotideshave
been used to inhibit cryptic exons or to activate regular
exons weakened by mutations via targeting of the oligo-
nucleotides to the desired transcript. This approach could
eventually lead to effective therapies for the correction of
erroneous splicing (reviewed in the work of Garcia-Blanco
et al.58). The tight regulation of FANCD2 expression and
activation and the presence of low-abundant wild-type
gene products associated with FANCD2 mutations should
render FANCD2 an ideal candidate for RNA-reprogram-
ming strategies such as spliceosome-mediated RNA trans-
splicing (SMaRT) (reviewed in the work of Mansﬁeld et
al.59).
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Web Resources
Accession numbers and URLs for data presented herein are as
follows:
ClustalW, ftp://ftp-igbmc.u-strasbg.fr/pub/ClustalX (for the poly-
peptide sequences compared using theWindows interfaceClus-
talX [v. 1.81, for the multiple sequence-alignment program])
CpG Island Explorer, http://bioinfo.hku.hk/cpgieintro.html (for
promoter analyses [v. 1.9, at the settings GC 60%, CpG O/E
ratio 0.7, and minimum length 500 nt)
Ensembl Genome Browser, http://www.ensembl.org/ (for FANCD2
genomic sequences [accession number ENSG00000144554]and
Fancd2 sequence information for other species)
ESEﬁnder, http://rulai.cshl.edu/tools/ESE/ (for analysis of regu-
latory splice sequences)
ExPASy, http://www.expasy.org/sprot/ (for the Swiss-Prot Fancd2
protein sequences of different species, including Homo sapiens)
GenBank, http://www.ncbi.nlm.nih.gov/Genbank/ (for FA-D2 [ac-
cession number NM_033084, 43 exons]) and FANCD2 [accession
number AF340183, 44 exons], used as the human FANCD2 cDNA
reference)
Human BLAT Search, http://genome.ucsc.edu/cgi-bin/hgBlat (for
genomic FANCD2 sequences)
Human Genome Variation Society, http://hgvs.org/ (for the mu-
tation nomenclature)
MaxEntScan, http://genes.mit.edu/burgelab/maxent/
Xmaxentscan_scoreseq_acc.html (for estimation of deduced
splice-acceptor function, with use of a maximum entropy
model)
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi
.nlm.nih.gov/Omim/ (for FA-A, -B, -C, -D1, -D2, -E, -F, -G, -I,
-J, -L, -M, -N, BRCA1, RAD51, RAD50, ATM/ATR, RAD50,Mich-
elin-tire baby syndrome, VACTERL-like association, holopro-
sencephaly, and Kartagener syndrome)
RepeatMasker, http://www.repeatmasker.org/ (for analysis of re-
petitive elements)
Rescue-ESE (http://genes.mit.edu/burgelab/rescue-ese (for analy-
sis of regulatory splice sequences)
Spliceﬁnder, http://www.uni-duesseldorf.de/rna/ (for predicted
splice-donor performance)
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